Sanofi (EPA:SAN)
France · Delayed Price · Currency is EUR | Market Cap | 104.35B |
| Revenue (ttm) | 45.93B |
| Net Income (ttm) | 9.11B |
| Shares Out | 1.22B |
| EPS (ttm) | 7.39 |
| PE Ratio | 16.43 |
| Forward PE | 10.38 |
| Dividend | 3.92 (4.57%) |
| Ex-Dividend Date | May 12, 2025 |
| Volume | 299,979 |
| Average Volume | 1,678,973 |
| Open | 85.42 |
| Previous Close | 85.76 |
| Day's Range | 85.24 - 86.56 |
| 52-Week Range | 76.15 - 110.88 |
| Beta | 0.37 |
| RSI | 47.57 |
| Earnings Date | Jan 29, 2026 |
About Sanofi
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases, neurology, oncology, and other medicines and vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B; influenza, booster, meningitis, and travel and endemic vaccines, that includes hepati... [Read more]
Financial Performance
In 2024, Sanofi's revenue was 44.29 billion, an increase of 7.73% compared to the previous year's 41.11 billion. Earnings were 5.56 billion, an increase of 2.96%.
Financial StatementsNews
Notable healthcare headlines for the week: Sanofi, Eli Lilly, and Novo Nordisk in focus
Get the latest healthcare stock updates, key drug price negotiations, and policy changes impacting the S&P 500.
Milestones Over Sales: The Sanofi Partnership Now Drives Novavax's Outlook
Sanofi Stock Drops After Confirming Raid, Tax Fraud Investigation
Sanofi stock dropped Wednesday after French authorities raided the drugmaker's Paris headquarters as part of a tax fraud investigation.
AI won't cure cancer, says Sanofi CEO
Paul Hudson, CEO of pharmaceuticals giant, Sanofi discusses the benefits and limitations of implementing AI across the healthcare sector.
Sanofi (SNY) Headquarters Raided in Tax Fraud Investigation
Sanofi (SNY) Headquarters Raided in Tax Fraud Investigation
Sanofi Faces Surprise HQ Search As French Authorities Expand Tax Probe
Sanofi SA's (NASDAQ: SNY) Paris headquarters received an unannounced visit on Tuesday as tax investigators, accompanied by prosecutors and specialist aides, searched the site amid a widening financial...
Sanofi Faces Surprise HQ Search As French Authorities Expand Tax Probe
Sanofi SA's (NASDAQ: SNY) Paris headquarters received an unannounced visit on Tuesday as tax investigators, accompanied by prosecutors and specialist aides, searched the site amid a widening financia...
Sanofi Paris HQ raided over tax fraud investigation involving Societe Generale
Sanofi's Paris HQ raided over tax fraud probe tied to Societe Generale financing. Read more here.
Sanofi (SNY) Investigated for Tax Fraud and Money Laundering
Sanofi (SNY) Investigated for Tax Fraud and Money Laundering
SNY & REGN's Dupixent Gets EU Nod for Chronic Spontaneous Urticaria
Sanofi/Regeneron's Dupixent wins EU nod for chronic spontaneous urticaria, marking its seventh approved indication across inflammatory diseases in the EU.
Sanofi (SNY) Gains EU Approval for Dupixent in Chronic Urticaria
Sanofi (SNY) Gains EU Approval for Dupixent in Chronic Urticaria
Sanofi (SNY) Gains European Nod for Dupixent in Treating Chronic Urticaria
Sanofi (SNY) Gains European Nod for Dupixent in Treating Chronic Urticaria
EU approves Sanofi and Regeneron’s Dupixent as first targeted therapy for chronic spontaneous urticaria in a decade
Please provide the article or its content so I can generate the meta description as per your instructions.
Sanofi And Regeneron : European Commission Approves Dupixent For CSU In Adults And Adolescents
(RTTNews) - Sanofi (SNY, SNYNF, SAN.PA) and Regeneron Pharmaceuticals Inc. (REGN) announced that the European Commission has approved Dupixent (dupilumab) as a first-line targeted treatment for modera...
Press Release: Sanofi and Regeneron's Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria
Sanofi and Regeneron's Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria
Press Release: Sanofi and Regeneron's Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria
Sanofi and Regeneron's Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria Approval based on phase 3 studies showing Dupixent significantly re...
Bayer Stroke Drug Hits Trial Goals, Analyst Sees Positive Data Readout From Bristol Myers' Milvexian After Failed Study
Bayer AG (OTC: BAYRY) released topline results from the Phase 3 OCEANIC-STROKE study, with its investigational, once daily, oral FXIa inhibitor asundexian. • BMY shares are climbing. Find out why her...
Sanofi (SNY) Study Reveals Cost Benefits in Digital Health Intervention
Sanofi (SNY) Study Reveals Cost Benefits in Digital Health Intervention
Texas AG Sues Sanofi And Bristol-Myers Over Alleged Failures To Warn About Risks Associated With Blood Thinner Drug
Texas Attorney General Ken Paxton escalated his campaign against major drugmakers this week, filing a new lawsuit accusing Sanofi SA (NASDAQ: SNY) and Bristol-Myers Squibb Co (NYSE: BMY) of conceali...
Sanofi (SNY) and Bristol Myers Squibb (BMY) Face Legal Action Over Plavix Marketing
Sanofi (SNY) and Bristol Myers Squibb (BMY) Face Legal Action Over Plavix Marketing
Texas AG Paxton takes aim at Sanofi, Bristol over Plavix
Bristol Myers, Sanofi sued by Texas over Plavix
Texas Attorney General Ken Paxton sued Bristol Myers Squibb and Sanofi , accusing the drugmakers of failing to disclose that Plavix, which is used to prevent blood clots, does not work effectively for...
Lifordi Immunotherapeutics Secures Strategic Investment from Sanofi Ventures and Additional Capital from Existing Investors
Burlington, Massachusetts--(Newsfile Corp. - November 18, 2025) - Lifordi Immunotherapeutics, Inc., a clinical-stage biotech company developing antibody-drug conjugates (ADCs) for the treatment of aut...
Lifordi Immunotherapeutics Secures Strategic Investment from Sanofi Ventures and Additional Capital from Existing Investors
BURLINGTON, Mass.--(BUSINESS WIRE)-- #ADCs--Lifordi Immunotherapeutics, Inc., a clinical-stage biotech company developing antibody-drug conjugates (ADCs) for the treatment of autoimmune and inflammato...
SNY Makes Notable Cross Below Critical Moving Average
In trading on Tuesday, shares of Sanofi (Symbol: SNY) crossed below their 200 day moving average of $50.97, changing hands as low as $50.48 per share. Sanofi shares are currently trading off about 2.4...